太极集团(600129) - 2025 Q2 - 季度业绩预告

Important Notice This performance forecast applies to situations where profitability is achieved but net profit declines by more than 50% year-on-year - This performance forecast applies to situations where profitability is achieved and net profit declines by more than 50% year-on-year[2] Key Performance Indicators for H1 2025 Performance Forecast | Indicator | Estimated Amount (CNY million) | Year-on-Year Decrease (CNY million) | Year-on-Year Decrease (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 139.00 | 355.61 | 71.90% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 120.00 | 349.95 | 74.47% | H1 2025 Performance Forecast This section details the company's preliminary financial estimates for the first half of 2025, indicating significant declines in net profit Performance Forecast Period This performance forecast covers the period from January 1 to June 30, 2025 - The performance forecast period is from January 1 to June 30, 2025[3] Performance Forecast Details Preliminary estimates indicate a significant year-on-year decline of over 70% in both net profit attributable to shareholders and non-recurring net profit for H1 2025 Detailed H1 2025 Performance Forecast Data | Indicator | Estimated Amount (CNY million) | Year-on-Year Decrease (CNY million) | Year-on-Year Decrease (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 139.00 | 355.61 | 71.90% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 120.00 | 349.95 | 74.47% | Audit Status Explanation The performance forecast data is unaudited, and investors should be aware of the associated risks - This performance forecast data has not been audited by a certified public accountant[3] H1 2024 Comparative Performance Review This section provides a review of the company's financial performance for the first half of 2024, serving as a benchmark for comparison Key Financial Indicators The total profit, net profit attributable to shareholders, and non-recurring net profit for H1 2024 are disclosed as a comparative baseline Key Financial Indicators for H1 2024 | Indicator | Amount (CNY million) | | :--- | :--- | | Total Profit | 596.43 | | Net Profit Attributable to Shareholders | 494.61 | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 469.95 | Earnings Per Share The earnings per share for the first half of 2024 are disclosed H1 2024 Earnings Per Share | Indicator | Amount (CNY/share) | | :--- | :--- | | Earnings Per Share | 0.89 | Analysis of Main Reasons for Performance Decline This section analyzes the primary factors contributing to the anticipated decline in the company's performance, including business operations and non-recurring items Impact on Main Business Operations Sales of key products, including gastrointestinal cold, anti-infective, and cough remedies, declined year-on-year due to policy impacts and inventory digestion, leading to a CNY 2.16 billion decrease in H1 2025 revenue - Sales of main products, including gastrointestinal cold, anti-infective, and cough remedies, decreased year-on-year due to relevant policies and continuous social inventory digestion[5] - The company maintains strong R&D investment, enhances product secondary development and new product R&D, and actively promotes professional academic promotion, marketing reform, operational control, and strict shipment management to boost terminal sales[5] H1 2025 Operating Revenue Change | Indicator | Change Amount (CNY billion) | | :--- | :--- | | Year-on-Year Decrease in Operating Revenue | 2.16 | Impact of Non-Recurring Gains and Losses Non-recurring gains and losses are expected to impact net profit attributable to shareholders by CNY 19 million, a decrease of approximately CNY 5.5 million year-on-year Impact of Non-Recurring Gains and Losses on Net Profit | Indicator | Estimated Impact Amount (CNY million) | Year-on-Year Decrease (CNY million) | | :--- | :--- | :--- | | Non-Recurring Gains and Losses Impact | 19.00 | 5.50 | Risk Warning This section highlights that there are no significant uncertainties affecting the accuracy of the performance forecast content - The company confirms no significant uncertainties exist that would affect the accuracy of this performance forecast[6] Other Explanatory Notes This section clarifies that the forecast data is preliminary and advises investors to exercise caution - The forecast data is preliminary, and the accurate financial figures will be based on the company's officially disclosed H1 2025 report[7] - Investors are advised to exercise caution regarding investment risks[7]